Earnings summaries and quarterly performance for HARTE HANKS.
Executive leadership at HARTE HANKS.
Board of directors at HARTE HANKS.
Research analysts who have asked questions during HARTE HANKS earnings calls.
Recent press releases and 8-K filings for HHS.
Harte Hanks Reports Q3 2025 Financial Results
HHS
Earnings
Demand Weakening
New Projects/Investments
- Harte Hanks reported revenue of $39.5 million for Q3 2025, a decrease from $47.6 million in Q3 2024, resulting in a net loss of $2.3 million (or $0.31 per diluted share) compared to net income of $0.1 million ($0.02 per diluted share) in the prior year period.
- EBITDA was $1.7 million and Adjusted EBITDA was $2.4 million for Q3 2025, down from $2.9 million and $4.1 million, respectively, in Q3 2024.
- The company maintained a strong liquidity position with $6.5 million in cash and cash equivalents and zero debt outstanding as of September 30, 2025, with up to $24 million available under its credit facility, which was extended to June 30, 2028.
- Harte Hanks highlighted momentum with a new Samsung partnership in its Customer Care segment and expects sequential improvement in Q4 2025 and beyond, anticipating positive EBITDA for the full-year 2025.
Nov 10, 2025, 9:34 PM
Quarterly earnings call transcripts for HARTE HANKS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more